Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-11-29
2009-12-29
Kam, Chih-Min (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S008100, C530S350000, C530S395000, C530S400000, C424S009100, C424S085100
Reexamination Certificate
active
07638487
ABSTRACT:
The present invention relates to methods of using lactoferrin (LF) to reduce pain in conditions associated with severe or intractable pain by administering a composition of lactoferrin either alone or in combination with other therapy for pain.
REFERENCES:
patent: 5561109 (1996-10-01), Mita et al.
patent: 5576299 (1996-11-01), Ando et al.
patent: 5712247 (1998-01-01), Wu et al.
patent: 5919913 (1999-07-01), Nuyens et al.
patent: 6066469 (2000-05-01), Kruzel et al.
patent: 6080559 (2000-06-01), Conneely et al.
patent: 6100054 (2000-08-01), Conneely et al.
patent: 6228614 (2001-05-01), Conneely et al.
patent: 6277817 (2001-08-01), Kruzel et al.
patent: 6333311 (2001-12-01), Nuijens et al.
patent: 6455687 (2002-09-01), Kruzel et al.
patent: 2002/0064524 (2002-05-01), Cevc
patent: 2002/0107283 (2002-08-01), Codd et al.
patent: 2003/0039651 (2003-02-01), Olmarker
patent: 2003/0077641 (2003-04-01), Laskowitz et al.
patent: 2003/0096763 (2003-05-01), Or et al.
patent: 2004/0009895 (2004-01-01), Varadhachary et al.
patent: 2004/0018190 (2004-01-01), Ando et al.
patent: 2005/0019342 (2005-01-01), Varadhachary et al.
patent: WO-98/33509 (1998-08-01), None
patent: WO-00/01730 (2000-01-01), None
patent: WO-02/03910 (2002-01-01), None
patent: WO-02080897 (2002-10-01), None
patent: WO-03/061688 (2003-07-01), None
Baraniuk et al, “Hypertonic Saline Nasal Provocation Stimulates Nociceptive Nerves, Substance P Release, and Glandular Mucous Exocytosis in Normal Humans,” Am J Respir Crit care Med vol. 160, 1999, pp. 655-662.
Brink, “Lactoferrin: The Bioactive Peptide that Fights Disease,”Life Extension Magazine, found at http://www.lef.org/LEFCMS/aspx/PringVersionMagic.aspx?CmsID=31812, Oct. 2000.
Eckmann, L. “Mucosal defences against Giardia,” Parasite Immunol. vol. 25 No. 5, May 2003, pp. 259-270.
Hayashida et al, “Lactoferrin enhances opioid-mediated analgesia via nitric oxide in the rat spinal cord,” Am J Physiol Regul Integr Comp Physiol 285, 2003; R306-R312.
Hayashida et al, “Novel function of bovine milk-derived lactoferrin on antinociception mediated by M-opioid receptor in the rat spinal cord,” Brain research 965, 2003, pp. 239-245.
Teschemacher, Hansjorg “Lactoferrin elicits opioid-mediated antinociception without development of toleence: central nNOS-1 set off duty?” American Journal Physiol. Regul Integr Comp Physiol 285, 2003, R302-R305.
Ho, R.C.S., “Pain in the Cancer Patient,” Ca Cancer J Clin, 1994: 44, 259-261.
Mercadante, S. “Pain treatment and outcomes for patients with advanced cancer who receive follow-up care at home.” Cancer, Apr. 15, 1999: 85 (8):1849-1858.
Griffin et al., On the receiving end V: Patients perceptions of the side effects of cancer chemotherapy in 1993, Annals of Oncology 7: 189-195, 1996.
Petrak Karel
Varadhachary Atul
Agennix Inc.
Fulbright & Jaworski L.L.P.
Kam Chih-Min
LandOfFree
Lactoferrin in the reduction of pain does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Lactoferrin in the reduction of pain, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lactoferrin in the reduction of pain will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4110966